Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the Netherlands / NCT05373810
Recruiting Observational

Registration Study Sarcoma

NCT05373810 · tracked via the Priya Life Science Netherlands tracker
Sponsor
Radboud University Medical Center
Phase
Observational
Started
2019-07-29
Last updated
2022-05-23

Condition(s) studied

Sarcoma

Investigational drug(s) / intervention(s)

Surgery

Surgery: all interventions are allowed

Study summary

The prospective and retrospective data collection on bone and soft tissue sarcoma is an observational cohort study aimed to collect clinical data and patient reported outcomes of all patients who have been diagnosed with bone or soft tissue sarcoma in the Netherlands. All patients diagnosed with bone or soft tissue sarcoma who are treated, planned for treatment or currently being treated, will be asked to participate in this project.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Histologically proven bone or soft tissue sarcoma, excluding Gastrointestinal Stromal Tumours Exclusion Criteria: * Altered mental status that would prohibit the understanding of and giving of informed consent

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Radiotherapiegroep Arnhem Netherlands Recruiting
Radboudumc Nijmegen Netherlands Recruiting

More Radboud University Medical Center trials in the Netherlands

Ten Year Follow-up in FSHD: the FOCUS 3 Study Recruiting
Measuring Athlete's Risk of Cardiovascular Events 3 (MARC-3) Enrolling by invitation
Factors Determining the Efficacy of Botulinum Toxin for Arm Tremor in Dystonia Active, not recruiting
STEPWISE Parkinson: A Smartphone Based Exercise Solution for Patients With Parkinson's Disease Recruiting
Preventive Dendritic Cell Vaccination for Lynch Syndrome Carriers Starting soon

Other trials for the same condition

Short Course of Radiotherapy Prior to Surgery of Soft Tissue Sarcomas Recruiting
9-ING-41 in Patients With Advanced Cancers Active, not recruiting
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05373810 on ClinicalTrials.gov ↗ ← All trials in the Netherlands